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Background
Live influenza vaccines trigger all major components of
the anti-flu immune response machinery and have been
included in the global WHO program on the pandemic
preparedness. Key advantages of using live vaccines
include a feasibility of intranasal administration, opportu-
nity to rapidly scale up production of the viral substance,
simplicity of vaccination, and robust protection against
antigenic drift variants of the virus. Use of certified cell
cultures for the cultivation of seasonal strains of influ-
enza along with biodegradable materials for constructing
delivery vehicles is considered one of the mainstream
approaches to the development of new generations of flu
vaccines.
We developed a live cultural influenza vaccine called
Vector-Flu, which is based on the cold-adapted virus
strain A/17/California/2009/38 (H1N1) and MDCK cell
line obtained from the certified cell culture depository.
Preclinical studies have demonstrated safety and high
immunogenicity of Vector-Flu in a ferret model.
Phase I of clinical trials was conducted on healthy
volunteers in the Medical Unit #163 in Koltsovo, Russia.
The trial pursued the following goals:1) Evaluation of
safety and tolerability.2) Evaluation of the humoral and
adaptive immune response using HI, ELISA and micro-
neutralization assay.3) Evaluation of the cellular immune
response, as measured by the cytokine release level in
response to the ex vivo stimulation of blood lympho-
cytes by the influenza virus.
Materials and methods
Cell culture
MDCK from Cell Culture Collection of SRC VB VEC-
TOR. Cells were passed in serum-free SFM4MegaVir
medium (USA). The characteristics of the MDCK cell
line were studied in accordance with WHO [1].
Viruses
The vaccine strain A/17/California/2009/38(H1N1) was
generated at the Institute of Experimental Medicine
(St. Petersburg, Russia) by reassortment of the cold-
adapted attenuated A/Leningrad/134/17/57 (H2N2)
master donor virus with the pandemic strain A/Califor-
nia/7/2009 (H1N1). The A/Chita/3/2009(H1N1) influ-
enza virus was obtained from VECTOR’s Collection of
Microorganisms.
Determination of influenza virus infectious activity
The infectious activity of influenza virus was determined
by titration in 10-12-day-old chick embryos. 10-fold
dilutions (0.2 ml) of virus-containing fluid were inocu-
lated into the allantoic cavity of chick embryos. The
embryos were incubated for 48 hours at a temperature
of 35°C. After the incubation, the allantoic fluid was
harvested from the embryos to determine the virus
infectious activity by agglutination reaction with 1%
chicken red blood cells. The virus titer was calculated
according to the Reed-Muench method and expressed
as log EID50/0.2 ml.
Control of immunogenicity of the vector-flu vaccine
Hemagglutination Inhibition (HI) test. HAI was performed
by a routine technique [2] with some modifications. The
assayed sera were pre-treated with the receptor destroying
enzyme (RDE). The hemagglutination reaction was
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performed with 1% chicken red blood cells (RBC). The
HAI titer was determined as the reciprocal dilution of the
last row which contained non-agglutinated RBC.
Microneutralization assay. The assay was performed in
compliance with the WHO guidelines [2] with some
modifications. MDCK cells supplemented with equal
volumes of serum and influenza virus were mixed and
incubated in 5% CO2 at 37°C. The presence of the virus
was detected by enzyme immunoassay using the mono-
clonal antibodies to type A influenza virus NP protein
(CDC, Atlanta). Neutralizing antibody titer was defined
as reciprocal of the highest serum dilution that provided
50% inhibition of the virus growth in cell culture.
Phase I of clinical trials included 3 arms:
Arm 1 (n = 20): a treatment group. Volunteers were
vaccinated using a single dose of the Vector-Flu vaccine
containing 106 EID50 of the influenza virus.
Arm 2 (n = 20): a treatment group. Volunteers were
vaccinated twice over a course of 10 days using Vector-
Flu vaccine containing 106 EID50 of the influenza virus.
Arm 3 (n = 20): a placebo control group. Volunteers
were injected twice over a course of 10 days using sterile
sodium chloride.
Results
Our findings show that the Vector-Flu has high tolerability
and no significant side effects. Dynamic changes of the
hematologic analysis values and urine test results obtained
after the immunization were within a normal range. Virus
was not detectable in nasal mucus and blood sera of the
healthy volunteers after a single and double injections as
early as at day 1, demonstrating a rapid clearance of the
live virus from the vaccination sites. Additionally, no indi-
cations of infection generalizations were observed.
A seroconversion level (number of subjects with >4x
increase of the antibody titer) was detected at 45% after
a single injection, as measured using HI assay. After the
second injection, peaks of immunogenic activity were
recorded at 2 and 3 weeks, and seroconversion level
rose up to 80%.
Activation of the Th2 immune response was measured
in whole blood cells. Post-vaccination cytokine indexes
were high and stable: 100% for IL-10 and TNFa, and
75% for IL-6.
Conclusions
Our findings show that the Vector-Flu has high toler-
ability and no significant side effects. Clinical trials of
the live cultural anti-influenza vaccine Vector-Flu have
been conducted in accordance with the protocol of clin-
ical trials and national and international clinical trial
guidelines (ICH GCP). The Ministry of Health of Russia
has granted a permission to advance to the phase II
trials for the Vector-Flu vaccine.
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